We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.24% | 204.50 | 203.50 | 204.50 | 204.50 | 200.00 | 202.00 | 62,827 | 09:27:45 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.31 | 194.61M |
TIDMOXB
RNS Number : 9918F
Oxford Biomedica PLC
23 May 2017
Oxford BioMedica Annual General Meeting
London, UK - 23 May 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
-- Resolution 7: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;
-- Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and
-- Resolution 9: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2017 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (19 May 2017) there were 3,088,326,065 1p ordinary shares in issue, each carrying one vote per share.
Votes Votes at at other Total Votes Chairman's proxy Votes Votes votes Resolution For Discretion Discretion Against Withheld cast Result ------------- --------------- ------------ ------------ ----------- ------------ ---------------- --------- Ordinary resolutions 1 1,888,465,188 802,799 6,958,793 604,970 398,641 1,897,230,391 Passed 2 1,601,919,465 928,694 6,958,793 4,701,911 282,721,528 1,897,230,391 Passed 3 1,880,264,095 868,254 6,958,793 1,126,450 8,012,799 1,897,230,391 Passed 4 1,880,712,558 872,425 6,958,793 664,300 8,022,315 1,897,230,391 Passed 5 1,813,674,842 880,635 6,958,793 75,322,036 394,085 1,897,230,391 Passed 6 1,887,924,882 925,661 6,958,793 857,070 563,985 1,897,230,391 Passed Special resolutions 7 1,774,042,262 1,002,090 6,958,793 1,619,809 113,607,437 1,897,230,391 Passed 8 1,887,104,129 1,002,090 6,958,793 1,557,942 607,437 1,897,230,391 Passed 9 1,879,803,796 1,001,125 6,958,793 9,042,530 424,147 1,897,230,391 Passed
- Ends -
For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 John Dawson, Chief Executive Officer 783 000 Tim Watts, Chief Financial Officer Consilium Strategic Communications Tel: +44 (0)20 Mary-Jane Elliott/Matthew Neal/Chris 3709 5700 Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSEFFDDFWSESI
(END) Dow Jones Newswires
May 23, 2017 09:03 ET (13:03 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions